## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.3% below STRENGTH zone (3.0-6.0%); PEG 1.07 fails VALUE criteria (<1.0); RSI 74 overbought. Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.7% MRS), overbought RSI (74).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($199.50)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Fisher Asset Management LLC Sells 436,290 Shares of Johnson & Johnson $JNJ**
- Source: MarketBeat | 20251201T102414 | Neutral | Relevance: 99%
- Fisher Asset Management LLC reduced its stake in Johnson & Johnson by 5.0% in the second quarter, selling 436,290 shares and holding 8,272,472 shares valued at approximately $1.26 billion. Despite this sale, Johnson & Johnson continues to attract significant institutional investment, with several other firms either increasing their holdings or initiating new positions. The article also notes recent analyst ratings, insider selling, and key financial metrics for JNJ.

**2. Trial testimony claims Johnson & Johnson hid the risks of talc products for 50 years**
- Source: Class Action Lawsuits | 20251201T142147 | Neutral | Relevance: 99%
- A former FDA commissioner testified in a class action trial that Johnson & Johnson concealed the health risks of its talc products for over 50 years, including asbestos contamination. The testimony accused J&J of pressuring scientists to hide findings of asbestos in their products. This bellwether trial in Los Angeles is part of a series of cases alleging J&J's talc products caused ovarian cancer or mesothelioma.

**3. VestGen Advisors LLC Sells 1,591 Shares of Johnson & Johnson $JNJ**
- Source: MarketBeat | 20251201T131928 | Somewhat-Bullish | Relevance: 99%
- VestGen Advisors LLC reduced its stake in Johnson & Johnson by 5.0%, selling 1,591 shares, while other institutional investors like Norges Bank and Vanguard increased their holdings. Johnson & Johnson declared a quarterly dividend of $1.30 per share. The article also details recent analyst ratings, insider transactions, and the company's price performance and financial metrics.

**4. Johnson & Johnson (JNJ): Exploring the Stockâ€™s Valuation Following Recent Trading Moves**
- Source: Simply Wall Street | 20251201T112755 | Neutral | Relevance: 99%
- This article examines Johnson & Johnson's (JNJ) stock valuation after recent trading moves, noting its strong share price momentum with a significant return over the past year. It discusses two valuation narratives: one suggesting the stock is fairly valued around $206.92 based on analyst consensus, and another from a Discounted Cash Flow (DCF) model indicating it might be undervalued by 46% at $384.12. The article highlights potential risks like litigation and loss of drug exclusivity while encouraging investors to explore different valuation perspectives.

**5. Shelton Capital Management Raises Stake in Johnson & Johnson $JNJ**
- Source: MarketBeat | 20251201T122644 | Somewhat-Bullish | Relevance: 99%
- Shelton Capital Management increased its stake in Johnson & Johnson (NYSE:JNJ) by 18.5% in the second quarter, owning 87,387 shares valued at $13.35 million. Other institutional investors like Vanguard Group Inc., Geode Capital Management LLC, Norges Bank, Northern Trust Corp, and Bank of New York Mellon Corp also adjusted their holdings. The article details JNJ's stock performance, recent quarterly earnings, dividend announcement, and analyst ratings, indicating a consensus "Moderate Buy" rating.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Guggenheim | $227 | $206 | +10% |
| 2025-12-02 | Barclays | $197 | $176 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Guggenheim | main | Buy |
| 2025-12-02 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.26M) |
| Sells | 7 ($4.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Insider selling cluster: $4.1M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.07 suggests fair value with growth premium. Forward P/E 17.8x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (2 raises, avg +11%). Insider selling cluster ($4.1M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $497.6B |
| Beta | 0.35 |
| 52W Range | $140.68 - $207.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.07 |
| Forward P/E | 17.8 |
| Current P/E | 18.9 |
| YoY Growth | 6.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.4% to -1.3% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.3pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.77), confirming momentum. RSI overbought at 74, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.33% (CS: 39) | Neutral |
| RSI_14 | 73.5 | Overbought |
| MACD Histogram | 0.77 | Bullish |
| vs SMA20 | 1.042x | Above |
| vs SMA50 | 1.073x | Above |
| vs SMA200 | 1.213x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $205.34
- **Stop Loss:** $199.50 (2.8% risk)
- **Target:** $211.18 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 128
- **Position Value:** $26,283.52
- **Portfolio %:** 26.28%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*